Ondansetron shows potential in irritable bowel syndrome with diarrhoea
27 Mar 2023
A study on titrated ondansetron for the treatment of irritable bowel syndrome with diarrhoea (IBS-D) has fallen short of meeting the endpoint due to being underpowered. However, when data from this study and two others were pooled in a meta-analysis, ondansetron appears to yield significant improvements in the composite endpoint set by the Food and Drug Administration (FDA), namely stool consistency and urgency.
Add-on pembrolizumab helps improve outcomes of relapsed, refractory Hodgkin lymphoma
25 Mar 2023
Adding pembrolizumab to chemotherapy consisting of ifosfamide, carboplatin, and etoposide (ICE) in the treatment of patients with relapsed or refractory classic Hodgkin lymphoma appears to be well tolerated and associated with better outcomes in comparison with reports from studies on chemotherapy-only regimens, according to data from a phase II study.
Sign Out
